Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.
Patients with non-Hodgkin lymphoma (NHL) are treated today with a cocktail of drugs referred to as CHOP (Cyclophosphamide, Hydroxyldaunorubicin, Oncovin, and Prednisone). Subsets of patients with NHL of germinal center origin bear oncogenic mutations in the EZH2 histone methyltransferase. Clinical t...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4262195?pdf=render |
_version_ | 1817971092968439808 |
---|---|
author | Sarah K Knutson Natalie M Warholic L Danielle Johnston Christine R Klaus Tim J Wigle Dorothy Iwanowicz Bruce A Littlefield Margaret Porter-Scott Jesse J Smith Mikel P Moyer Robert A Copeland Roy M Pollock Kevin W Kuntz Alejandra Raimondi Heike Keilhack |
author_facet | Sarah K Knutson Natalie M Warholic L Danielle Johnston Christine R Klaus Tim J Wigle Dorothy Iwanowicz Bruce A Littlefield Margaret Porter-Scott Jesse J Smith Mikel P Moyer Robert A Copeland Roy M Pollock Kevin W Kuntz Alejandra Raimondi Heike Keilhack |
author_sort | Sarah K Knutson |
collection | DOAJ |
description | Patients with non-Hodgkin lymphoma (NHL) are treated today with a cocktail of drugs referred to as CHOP (Cyclophosphamide, Hydroxyldaunorubicin, Oncovin, and Prednisone). Subsets of patients with NHL of germinal center origin bear oncogenic mutations in the EZH2 histone methyltransferase. Clinical testing of the EZH2 inhibitor EPZ-6438 has recently begun in patients. We report here that combining EPZ-6438 with CHOP in preclinical cell culture and mouse models results in dramatic synergy for cell killing in EZH2 mutant germinal center NHL cells. Surprisingly, we observe that much of this synergy is due to Prednisolone - a glucocorticoid receptor agonist (GRag) component of CHOP. Dramatic synergy was observed when EPZ-6438 is combined with Prednisolone alone, and a similar effect was observed with Dexamethasone, another GRag. Remarkably, the anti-proliferative effect of the EPZ-6438+GRag combination extends beyond EZH2 mutant-bearing cells to more generally impact germinal center NHL. These preclinical data reveal an unanticipated biological intersection between GR-mediated gene regulation and EZH2-mediated chromatin remodeling. The data also suggest the possibility of a significant and practical benefit of combining EZH2 inhibitors and GRag that warrants further investigation in a clinical setting. |
first_indexed | 2024-04-13T20:42:18Z |
format | Article |
id | doaj.art-4dd56e327a7d4f3e9e537bcf0baa99bb |
institution | Directory Open Access Journal |
issn | 1932-6203 |
language | English |
last_indexed | 2024-04-13T20:42:18Z |
publishDate | 2014-01-01 |
publisher | Public Library of Science (PLoS) |
record_format | Article |
series | PLoS ONE |
spelling | doaj.art-4dd56e327a7d4f3e9e537bcf0baa99bb2022-12-22T02:30:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01912e11184010.1371/journal.pone.0111840Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.Sarah K KnutsonNatalie M WarholicL Danielle JohnstonChristine R KlausTim J WigleDorothy IwanowiczBruce A LittlefieldMargaret Porter-ScottJesse J SmithMikel P MoyerRobert A CopelandRoy M PollockKevin W KuntzAlejandra RaimondiHeike KeilhackPatients with non-Hodgkin lymphoma (NHL) are treated today with a cocktail of drugs referred to as CHOP (Cyclophosphamide, Hydroxyldaunorubicin, Oncovin, and Prednisone). Subsets of patients with NHL of germinal center origin bear oncogenic mutations in the EZH2 histone methyltransferase. Clinical testing of the EZH2 inhibitor EPZ-6438 has recently begun in patients. We report here that combining EPZ-6438 with CHOP in preclinical cell culture and mouse models results in dramatic synergy for cell killing in EZH2 mutant germinal center NHL cells. Surprisingly, we observe that much of this synergy is due to Prednisolone - a glucocorticoid receptor agonist (GRag) component of CHOP. Dramatic synergy was observed when EPZ-6438 is combined with Prednisolone alone, and a similar effect was observed with Dexamethasone, another GRag. Remarkably, the anti-proliferative effect of the EPZ-6438+GRag combination extends beyond EZH2 mutant-bearing cells to more generally impact germinal center NHL. These preclinical data reveal an unanticipated biological intersection between GR-mediated gene regulation and EZH2-mediated chromatin remodeling. The data also suggest the possibility of a significant and practical benefit of combining EZH2 inhibitors and GRag that warrants further investigation in a clinical setting.http://europepmc.org/articles/PMC4262195?pdf=render |
spellingShingle | Sarah K Knutson Natalie M Warholic L Danielle Johnston Christine R Klaus Tim J Wigle Dorothy Iwanowicz Bruce A Littlefield Margaret Porter-Scott Jesse J Smith Mikel P Moyer Robert A Copeland Roy M Pollock Kevin W Kuntz Alejandra Raimondi Heike Keilhack Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. PLoS ONE |
title | Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. |
title_full | Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. |
title_fullStr | Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. |
title_full_unstemmed | Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. |
title_short | Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. |
title_sort | synergistic anti tumor activity of ezh2 inhibitors and glucocorticoid receptor agonists in models of germinal center non hodgkin lymphomas |
url | http://europepmc.org/articles/PMC4262195?pdf=render |
work_keys_str_mv | AT sarahkknutson synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT nataliemwarholic synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT ldaniellejohnston synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT christinerklaus synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT timjwigle synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT dorothyiwanowicz synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT brucealittlefield synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT margaretporterscott synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT jessejsmith synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT mikelpmoyer synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT robertacopeland synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT roympollock synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT kevinwkuntz synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT alejandraraimondi synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas AT heikekeilhack synergisticantitumoractivityofezh2inhibitorsandglucocorticoidreceptoragonistsinmodelsofgerminalcenternonhodgkinlymphomas |